A phase II/III trial investigating the immunogenicity of early versus late immunisation with pneumococcal 7-valent CRM197 vaccine conjugate [Prevenar; Wyeth] + pneumococcal vaccine [polysaccharide 23-valent pneumococcal vaccine] in post-allogeneic stem cell transplant (SCT) patients.

Trial Profile

A phase II/III trial investigating the immunogenicity of early versus late immunisation with pneumococcal 7-valent CRM197 vaccine conjugate [Prevenar; Wyeth] + pneumococcal vaccine [polysaccharide 23-valent pneumococcal vaccine] in post-allogeneic stem cell transplant (SCT) patients.

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 13 Apr 2015

At a glance

  • Drugs Pneumococcal 7-valent CRM197 vaccine conjugate; Pneumococcal vaccine
  • Indications Pneumococcal infections
  • Focus Pharmacodynamics
  • Sponsors Wyeth
  • Most Recent Events

    • 28 Jan 2010 Secondary endpoint results published in Vaccine
    • 15 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top